25 September 2026 · The Pharmacist
Cochrane review highlights mifepristone for emergency contraception
A newly published Cochrane systematic review indicates that mifepristone, an established medicine traditionally utilised in abortion care, could serve as an effective yet overlooked option for emergency contraception. According to the evidence-based analysis, mifepristone is associated with preventing more pregnancies than several standard morning-after pills currently in use, while also presenting fewer reported side effects than existing oral regimens and copper intrauterine devices (IUDs).
Cochrane reviews are widely regarded across clinical sectors as the gold standard for evaluating evidence-based health interventions. In this analysis, the evaluation focused on comparing the comparative performance and adverse effect profile of mifepristone against established emergency contraceptive methods, highlighting its potential utility as a reliable post-coital intervention for patients.
The provided summary details the clinical comparison against alternative oral emergency contraceptives and copper IUDs, but it does not outline immediate alterations to national prescribing formularies or product licensing frameworks. Consequently, current clinical practice and supply models remain unchanged pending further evaluation by domestic health authorities. For UK online pharmacies and digital health brands, any future operational adoption of mifepristone within emergency hormonal contraception services would depend on formal updates to national clinical guidelines and marketing authorisations.